Toronto Dominion Bank Raises Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Toronto Dominion Bank lifted its position in United Therapeutics Co. (NASDAQ:UTHR) by 22.6% during the 3rd quarter, HoldingsChannel reports. The firm owned 5,546 shares of the biotechnology company’s stock after acquiring an additional 1,021 shares during the quarter. Toronto Dominion Bank’s holdings in United Therapeutics were worth $1,987,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in UTHR. ClariVest Asset Management LLC increased its stake in United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 42 shares during the last quarter. Innealta Capital LLC purchased a new position in shares of United Therapeutics in the second quarter valued at $33,000. USA Financial Formulas bought a new stake in United Therapeutics in the third quarter worth $33,000. Brooklyn Investment Group purchased a new stake in United Therapeutics during the third quarter valued at $33,000. Finally, Capital Performance Advisors LLP bought a new position in United Therapeutics during the third quarter valued at $82,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Trading Up 0.1 %

NASDAQ UTHR opened at $361.81 on Monday. The stock has a market cap of $16.15 billion, a PE ratio of 15.89, a PEG ratio of 1.05 and a beta of 0.54. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $417.82. The company’s 50-day moving average price is $369.94 and its 200-day moving average price is $342.71.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. During the same period last year, the company posted $5.38 earnings per share. The company’s quarterly revenue was up 22.9% compared to the same quarter last year. As a group, sell-side analysts forecast that United Therapeutics Co. will post 25.22 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on UTHR shares. Wells Fargo & Company upped their target price on shares of United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research report on Tuesday, August 20th. LADENBURG THALM/SH SH upped their price objective on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Argus lifted their target price on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. The Goldman Sachs Group increased their price target on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a report on Friday, November 1st. Finally, Jefferies Financial Group lifted their price objective on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research note on Monday, September 23rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $370.86.

Insiders Place Their Bets

In related news, CFO James Edgemond sold 7,796 shares of the company’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $354.04, for a total value of $2,760,095.84. Following the completion of the sale, the chief financial officer now directly owns 4,264 shares of the company’s stock, valued at $1,509,626.56. This represents a 64.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Nilda Mesa sold 224 shares of the firm’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $412.28, for a total transaction of $92,350.72. Following the transaction, the director now directly owns 5,783 shares in the company, valued at $2,384,215.24. This trade represents a 3.73 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 119,340 shares of company stock worth $44,765,530. 11.90% of the stock is currently owned by company insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.